iPS Cell Differentiation Using ILV and GLP-1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for differentiating induced pluripotent stem (iPS) cells into glucose-responsive, insulin-secreting progeny, which is crucial for developing effective treatments for diabetes, particularly type 1 diabetes.
Innovation Solution
The use of indolactam V (ILV) and glucagon-like peptide-1 (GLP-1) in a culture medium to differentiate iPS cells into glucose-responsive, insulin-producing cells, allowing for the production of patient-specific insulin-producing cells that can model disease pathogenesis and provide personalized therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional differentiation methods are used for iPS cells, then the differentiation process is simple, but the cells fail to achieve glucose-responsive insulin secretion
Solution Approach 1:
The patent applies parameter changes by systematically varying culture conditions including medium composition (serum-free vs. serum-containing), growth factor concentrations (FGF10, RA, CYC, ILV, GLP-1), and temporal parameters (differentiation time points from 7 to 28 days). These parameter modifications enable the transition from undifferentiated iPS cells to glucose-responsive insulin-secreting cells, resolving the contradiction between achieving reliable functional output and maintaining protocol simplicity.
Solution Approach 2:
The differentiation protocol is segmented into distinct temporal stages: early differentiation (days 7-14) involving formation of pancreatic progenitor cells, mid-differentiation (days 15-21) characterized by beta-cell lineage commitment, and late differentiation (days 22-28) achieving functional insulin secretion. This segmentation allows optimization of each stage independently, improving overall reliability while managing complexity through structured progression.
2Adaptability or versatility
If patient-specific iPS cells are derived and differentiated, then personalized therapy can be achieved, but the process time and cost increase
Solution Approach 1:
The patent implements preliminary action by establishing a standardized differentiation protocol that can be applied to any patient-specific iPS cell line. The protocol prepares all necessary culture conditions, growth factor combinations, and temporal parameters in advance, allowing rapid execution once patient-specific cells are obtained. This reduces the time required for personalized therapy while maintaining adaptability across different patient samples.
3Reliability
If serum-containing medium is used for iPS cell culture, then cell growth is supported, but contamination risk and variability increase
Solution Approach 1:
The patent applies the extraction principle by removing serum from the culture medium formulation and replacing it with defined serum-free supplements. This extraction of the variable serum component eliminates contamination risks and batch-to-batch variability associated with serum products, while the defined alternative supplements maintain essential growth support functions, thereby improving reliability without significantly complicating medium preparation.
Data Source
AI summary
This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.